AstraZeneca gets $76 million in Prilosec decision

Share this article:

AstraZeneca has been awarded $76 million in damages in a ruling over Apotex's sales of omeprazole, a generic version of AZ's Prilosec, between 2004 and 2007. That amount represents the equivalent of 50% of Apotex's profits during the three-and-a-half years it sold the drug.

According to a statement from AZ, US District Judge Denise Cote's decision upheld two AstraZeneca formulation patents covering Prilosec, and found that Apotex's generic omeprazole formulation infringed on those patents. Since a 2007 decision had already settled the patent infringement issue, the amount of damages was the only issue left to be resolved in the current decision. Apotex had requested a judgment of less than 7%, noting that by November 2003, three other generic versions of Prilosec had already entered the market.

However, Reuters reported, Cote noted that two of those versions were under the threat of patent litigation, while the third lacked the manufacturing capacity to meet full market demand. Because of that, she said, Apotex's version would likely have created significant price reductions on Prilosec, and represented a "golden opportunity" for the company.

The $76-million figure does not include interest, and both sides have a Dec. 6 deadline to present a proposed settlement amount that does include interest.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.